Susquehanna International Group
PVLA

Susquehanna International Group’s Palvella Therapeutics PVLA Stock Holding History

Susquehanna International Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Buy
141,600
+103,400
+271% +$10.8M ﹤0.01% 2382
2025
Q4 		$4M Buy
38,200
+22,500
+143% +$1.92M ﹤0.01% 4387
2025
Q3 		$984K Buy
15,700
+5,800
+59% +$259K ﹤0.01% 7405
2025
Q2 		$223K Buy
+9,900
New +$232K ﹤0.01% 10985
2022
Q4 		– Sell
-296
Closed -$27K – 13905
2022
Q3 		$27K Sell
296
-42
-12% -$5.42K ﹤0.01% 12495
2022
Q2 		$50K Sell
338
-372
-52% -$67.9K ﹤0.01% 11977
2022
Q1 		$172K Buy
710
+266
+60% +$69.9K ﹤0.01% 11421
2021
Q4 		$134K Sell
444
-210
-32% -$67.3K ﹤0.01% 11919
2021
Q3 		$270K Sell
654
-1,114
-63% -$388K ﹤0.01% 10825
2021
Q2 		$542K Buy
+1,768
New +$388K ﹤0.01% 9390
2020
Q4 		– Sell
-406
Closed -$67K – 11842
2020
Q3 		$67K Buy
+406
New +$92.4K ﹤0.01% 10108
2019
Q4 		– Sell
-1,261
Closed -$344K – 10822
2019
Q3 		$344K Buy
+1,261
New +$488K ﹤0.01% 8007
2018
Q2 		– Sell
-306
Closed -$167K – 10568
2018
Q1 		$167K Buy
+306
New +$189K ﹤0.01% 8456

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Susquehanna International Group's PVLA Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 18,808 shares worth $2.34M. The stake represents ﹤0.01% of the portfolio and ranks #5798 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in PVLA as recently as Q3 2025.

Susquehanna International Group first reported a position in PVLA in Q2 2015 and has held it in 24 quarters since. The position peaked at $3.2M in Q1 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Susquehanna International Group held 18,808 shares of Palvella Therapeutics worth $2.34M as of Q1 2026.
  • Palvella Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Palvella Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5798 holding.
  • Susquehanna International Group first reported a position in Palvella Therapeutics in Q2 2015 and has held it in 24 quarters since.
  • Susquehanna International Group's Palvella Therapeutics position peaked at $3.2M in Q1 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.